Loading the latest PSX data…
Loading the latest PSX data…
BF Biosciences LimitedShariah-compliant
+0.87 (+0.64%) today
Market closed, last update Nov 17, 2026 7:10 AMThe BF Biosciences share price was Rs 136.13 (+0.64%) at the last PSX update (Nov 17, 2026 7:10 AM). BFBIO is a pharmaceuticals stock with a market value of Rs 12.0bn.
Last session's range16 Nov 2026
135.2731% up the range138.05
52-week range
117.2031% up the range177.99
Price limits (circuit breakers)
121.7353% up the range148.79
BFBIO ranks better than 44% of the 309 liquid PSX stocks we score. Each factor is a 0-100 rank (value is ranked half within pharmaceuticals). Education only, not a buy or sell signal.
−0.6% over 6M(KSE-100 +4.9%)
Daily bars from PSX's end-of-day market summary. Prices before a bonus issue, right issue or split are adjusted so the chart stays continuous; cash dividends are not taken out.
Full-screen BFBIO chart with levelsDownload BFBIO price history (CSV)Compare BFBIO with GLAXO
From daily closes to 2026-11-16. A description of the trend, not a forecast.
Trend reading
Uptrend
Down4 up · 1 down signalsUp
| S2 | S1 | Pivot | R1 | R2 |
|---|---|---|---|---|
| 133.70 | 134.92 | 136.48 | 137.70 | 139.26 |
+51.6% over 5 years
Monthly closing prices from the PSX Data Portal, since 2024.
| Announced | Period | Payout | Profit after tax | EPS (Rs) | Books close |
|---|---|---|---|---|---|
| 28 Oct 11:43 | 1st quarter to 30 Sept | None | Rs 184.9m | 2.09 | – |
| 29 Sept 12:44 | Full year to 30 Jun | None | Rs 632.1m | 7.16 | 21 Oct – 28 Oct |
| 28 Apr 14:48 | 9 months to 31 Mar | None | Rs 464.9m | 5.26 | – |
| Measure | 2026 | 2025 |
|---|---|---|
| Sales growth | +62.1% | – |
| Profit growth | +41.4% | – |
| EPS growth | +29.7% | – |
| Net margin | 6.7% | 7.7% |
| Measure | Q1 2027 | Q3 2026 | Q2 2026 | Q1 2026 |
|---|---|---|---|---|
| Sales growth | +14.5% | – | – | – |
| Profit growth | +15.9% | – | – | – |
| EPS growth | +15.5% | – | – | – |
| Net margin | 6.6% | 5.5% | 7.0% | 6.6% |
| Line item | 2026 | 2025 |
|---|---|---|
| Sales | Rs 9.5bn | Rs 5.8bn |
| Profit after tax | Rs 632m | Rs 447m |
| Earnings per share (Rs) | 7.16 | 5.52 |
| Line item | Q1 2027 | Q3 2026 | Q2 2026 | Q1 2026 |
|---|---|---|---|---|
| Sales | Rs 2.8bn | Rs 2.1bn | Rs 2.7bn | Rs 2.4bn |
| Profit after tax | Rs 185m | Rs 118m | Rs 188m | Rs 160m |
| Earnings per share (Rs) | 2.09 | 1.33 | 2.13 | 1.81 |
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Gross margin | 43.2% | 39.2% | 41.9% | – |
| Net margin | 6.7% | 7.7% | 10.5% | – |
| EPS growth | 29.7% | -9.4% | – | – |
| PEG | 0.67 | -3.27 | – | – |
Rupee amounts from PSX filings (thousands converted to Rs m/bn). Data by Capital Stake via the PSX Data Portal; standardised, so it can differ from the annual report. Latest quarter (Q1 2027) EPS rose 15.5% from the same quarter a year earlier.
| Measure | BFBIO | Sector median | Reading |
|---|---|---|---|
| P/E | 18.3 | 12.2 | Dearer than peers |
| Dividend yield | – | 5.1% | – |
| Net margin | 6.7% | 9.4% | Below peers |
| EPS growth | +29.7% | +32.9% | Below peers |
| 1-year return | −10.1% | −14.7% | Above peers |
Sector P/E check. At the sector's median P/E of 12.2, last year's EPS of Rs 7.16 would price BFBIO at about Rs 87.15 (−36% from today). A rough yardstick only: sectors hold very different businesses, and the market prices future profits, not last year's.
Estimate a fair value for BFBIO (Graham, Lynch, DCF)BFBIO pivot levels
Ratios as published on the PSX Data Portal (standardised by Capital Stake), latest financial year on the right.
Work out your BFBIO dividend income after tax
PSX quotes payouts as a percentage of face value; cash per share assumes the usual Rs 10 face value. You get the dividend if you own the shares before the books close.
Market value
11th of 18
Rs 12.0bn
P/E (cheapest first)
10th of 13
18.3
1-year return
7th of 15
-10.1%
EPS growth
8th of 15
29.7%
Net margin
10th of 16
6.7%
danioPSX score
9th of 13
44/100
| GLAXOGlaxoSmithKline Pakistan Limited | Rs 108.1bn | +0.96% | 9.8 | 6.1% | −13.9% | 89 |
| ABOTAbbott Laboratories (Pakistan) Limited | Rs 98.3bn | +0.39% | 10.6 | 4.4% | −8.1% | 80 |
| HALEONHaleon Pakistan Limited | Rs 80.7bn | −1.06% | 12.4 | 3.6% | −15.7% | 65 |
| HINOONHighnoon Laboratories Limited | Rs 50.7bn | −0.30% | 12.3 | 5.4% | −15.4% | 78 |
| SEARLThe Searle Company Limited | Rs 46.7bn | +0.27% | 12.0 | – | −22.9% | 53 |
| AGPAGP Limited | Rs 43.5bn | −0.59% | 24.3 | 5.1% | −16.6% | 50 |
| HPLHoechst Pakistan Limited | Rs 38.5bn | +0.14% | 11.0 | 6.9% | −2.5% | – |
| FEROZFerozsons Laboratories Limited | Rs 15.9bn | +0.67% | 23.1 | 1.6% | −8.8% | 39 |
| CPHLCiti Pharma Ltd. | Rs 14.5bn | +0.19% | 17.8 | – | −21.6% | 31 |
| GSKCHGlaxoSmithKline Consumer Healthcare | Rs 14.1bn | −3.13% | – | – | – | – |
| BFBIOThis stock · BF Biosciences Limited | Rs 12.0bn | +0.64% | 18.3 | – | −10.1% | 44 |
| MACTERMacter International Limited | Rs 11.8bn | −1.58% | 3.7 | – | −28.2% | 51 |
| SAPLSanofi-Aventis Pakistan Limited | Rs 8.4bn | 0.00% | – | – | – | – |
| OTSUOtsuka Pakistan Limited | Rs 5.7bn | +5.78% | 11.6 | – | +35.9% | 65 |
| LIVENLiven Pharma Limited | Rs 4.9bn | +10.00% | – | – | −9.0% | 11 |
Swipe the table sideways for more columns.
No director or substantial-shareholder trades in BFBIO read from PSX notices yet.
Read automatically (OCR) from the disclosure images companies file with PSX under Regulation 5.6.1(d). A digit can be misread, so check the original notice before relying on a figure. Value = shares × price. Not investment advice. All PSX insider trades
BF Biosciences Limited ("BFBL", "Company", or the "Issuer") was incorporated as an unlisted public limited company under the Companies Ordinance, 1984 (now Companies Act, 2017) in 2006, and operates within the pharmaceutical industry. BFBL is a 80%:20% joint venture between Ferozsons Laboratories Limited and the Bagó Group of Argentina. The Company's core operations involve the import, manufacturing, marketing and distribution of pharmaceutical products.
Where the price sits in its 52-week range
Low 117.2031% of the way upHigh 177.99
Data: PSX Data Portal (Nov 17, 2026 7:10 AM); company data refreshed 17 Nov; daily bars from PSX market summaries; five-year record from danioPSX research. Logos are trademarks of their owners. Not a recommendation to buy or sell BFBIO. Official PSX page for BFBIO